LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Lista de Ações・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.94 -3

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.9

Máximo

2.04

Indicadores-chave
By Trading Economics
Rendimento	2.6M -39M
Funcionários	150
EBITDA	-1.4M -39M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+335.5% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	225M 787M
Abertura anterior	4.94
Fecho anterior	1.94

Sentimento de Notícias

By Acuity

35%

65%

98 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

1.18 / 1.69 Suporte e Resistência

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de mai. de 2026, 23:10 UTC

Ações em Alta

Stocks to Watch: Agilysys, XP

18 de mai. de 2026, 18:44 UTC

Grandes Movimentos do Mercado

Claritev Shares Recover After Comments About DOJ

18 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 de mai. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

18 de mai. de 2026, 20:25 UTC

Ganhos

Correct: XP 1Q Total Client Assets BRL1.53T

18 de mai. de 2026, 20:23 UTC

Ganhos

XP 1Q Total Client Assets BRL1.53B

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Adj EPS BRL2.49 >XP

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Rev BRL4.73B >XP

18 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 de mai. de 2026, 19:00 UTC

Ganhos

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 de mai. de 2026, 18:52 UTC

Conversa de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 de mai. de 2026, 18:17 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 de mai. de 2026, 17:22 UTC

Conversa de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 de mai. de 2026, 16:57 UTC

Aquisições, Fusões, Aquisições de Empresas

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 de mai. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Doesn't Set Out Financial Details of Deal

18 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 de mai. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Buys Canada's Modern Group of Companies

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

335.5% parte superior

Previsão para 12 meses

Média 8.71 USD 335.5%

Máximo 14 USD

Mínimo 3.85 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.18 / 1.69Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimento

By Acuity

98 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.